Clinical trial · Observational
Evaluation of Tissue and Circulating microRNA Profiles in Patients With Hepatocellular Carcinoma Subjected to Thermal Ablation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objectives of this research project concern the identification of microRNAs circulating and of serum metabolites predictive of treatment response in patients with early stage hepatocellular carcinoma undergoing locoregional treatment with thermoablation. In addition, the molecular mechanisms involved in reprogramming will be identified metabolic via bioinformatics analysis and pretreatment liver biopsy analysis and analysis of screening on patient-derived primary lines for personalized therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocarcinoma | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- circulant microRNA
- timeFrame
- At baseline, at 24 hours, 1 month, 3 months
- description
- micro-RNAs differentially expressed between the complete response and disease residue groups
- measure
- tissue microRNA
- timeFrame
- At baseline
- description
- micro-RNAs differentially expressed between the complete response and disease residue groups
- measure
- Metabolomic analysis
- timeFrame
- At baseline, 24 hours, 1 month, 3 months
- description
- Identification of circulating metabolites differentially expressed between the complete response and disease residue groups
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 64 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 * Diagnosis of hepatocarcinoma confirmed by radiology (LIRADS criteria/triphasic diagnostics) or by biopsy. * Indication for thermoablation treatment (for radiofrequency) based on the judgment of the hepatologist/surgeon. * Informed consent signed by the patient. Exclusion Criteria: * Presence of metastatic liver lesions of other origins. * History of liver transplant. * Severe, uncorrectable coagulopathy, contraindicating liver biopsy (where necessary) or ablative procedure. * Patient refusal to participate in the study or inability to obtain informed consent. * Pregnant women.
References
Publications (0)
Data not yet available